Sugi Predict

Sugi Predict / Compounds / SCHEMBL1194573

SCHEMBL1194573

SCHEMBL1194573

O=S(=O)(C=Cc1ccc(Br)cc1)Cc1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ PTGES2 Q9H7Z7 3/20 0.44
▸ EGFR P00533 2/20 0.40
▸ ERBB2 P04626 2/20 0.40
▸ GPR183 P32249 3/20 0.40
▸ PKM P14618 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ POLB P06746 2/20 0.37
▸ CTDSP1 Q9GZU7 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3678125 1.00 KMT2A (0.46) KMT2AMEN1PTGES2EGFRERBB2
SCHEMBL1194097 1.00 KMT2A (0.46) KMT2AMEN1PTGES2EGFRERBB2
SCHEMBL1194571 1.00 KMT2A (0.46) KMT2AMEN1PTGES2EGFRERBB2
SCHEMBL1194095 1.00 KMT2A (0.46) KMT2AMEN1PTGES2EGFRERBB2
SCHEMBL1193131 0.92 PTGES2 (0.40) KMT2AMEN1PTGES2MAPTNPC1
SCHEMBL1193128 0.92 PTGES2 (0.40) KMT2AMEN1PTGES2MAPTNPC1
SCHEMBL1194500 0.92 KMT2A (0.51) KMT2AMEN1GPR183PKMMAPT
SCHEMBL1194436 0.92 KMT2A (0.51) KMT2AMEN1GPR183PKMMAPT
SCHEMBL1194433 0.92 KMT2A (0.51) KMT2AMEN1GPR183PKMMAPT
SCHEMBL5872228 0.84 APP (0.39) KMT2AMEN1PTGES2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027330-B1 STYRYL SULFONE ANTICANCER AGENTS UNIV TEMPLE (US) 2004-12-08 — — EP claimed
EP-1180024-B1 Z-STYRYL SULFONE ANTICANCER AGENTS UNIV TEMPLE (US) 2004-02-04 — — EP claimed
EP-1027330-A4 STYRYL SULFONE ANTICANCER AGENTS UNIV TEMPLE (US) 2003-09-10 — — EP claimed
US-20030114538-A1 Styryl sulfone anticancer agents TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2003-06-19 — — US claimed
US-6548553-B2 Therapy of proliferative disease other than prostate or breast cancer comprising administering styryl sulfone derivative TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2003-04-15 — — US claimed
US-6414034-B1 ANTICANCER AGENTS TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2002-07-02 — — US claimed
EP-1180024-A4 Z-STYRYL SULFONE ANTICANCER AGENTS UNIV TEMPLE (US) 2002-06-19 — — EP claimed
US-6359013-B1 BREAST AND PROSTATE CANCER; AFFECT THE MAPK SIGNAL TRANSDUCTION PATHWAY, THEREBY TUMOR CELL GROWTH; INHIBIT THE GROWTH OF TUMOR CELLS WITHOUT AFFECTING NORMAL CELLS; 4-FLUOROSTYRYL 4-BROMOBENZYL SULFONE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2002-03-19 — — US claimed
US-20020022666-A1 Styryl sulfone anticancer agents TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2002-02-21 — — US claimed
EP-1180024-A1 Z-STYRYL SULFONE ANTICANCER AGENTS Temple University of the Commonwealth System of Higher Education (US) 2002-02-20 — — EP claimed
US-6201154-B1 Z-styryl sulfone anticancer agents TEMPLE UNIVERSITY-OF THE COMMONWEALTH OF HIGHER EDUCATION 2001-03-13 — — US claimed
WO-2000059494-A1 STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2000-10-12 — — WO claimed
WO-2000057872-A1 Z-STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2000-10-05 — — WO claimed
EP-1027330-A1 STYRYL SULFONE ANTICANCER AGENTS Temple University of the Commonwealth System of Higher Education (US) 2000-08-16 — — EP claimed
WO-1999018068-A1 STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 1999-04-15 — — WO claimed
US-9713597-B2 Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone ONCONOVA THERAPEUTICS, INC. (US) 2017-07-25 — — US disclosed
US-20150265549-A1 STABLE AQUEOUS FORMULATION OF (E)-4-CARBOXYSTYRYL-4-CHLOROBENZYL SULFONE ONCONOVA THERAPEUTICS, INC (US) 2015-09-24 — — US disclosed
WO-2000057872-A1 Z-STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2000-10-05 — — WO disclosed
EP-1027330-A1 STYRYL SULFONE ANTICANCER AGENTS Temple University of the Commonwealth System of Higher Education (US) 2000-08-16 — — EP disclosed
WO-1999018068-A1 STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 1999-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114538-A1 Styryl sulfone anticancer agents BCL2, MCL1, BCL2A1 KMT2A 401/4885MEN1 1011/4885PTGES2 4127/4885
US-20020022666-A1 Styryl sulfone anticancer agents BCL2, MCL1, BCL2A1 KMT2A 401/4885MEN1 1011/4885PTGES2 4127/4885
US-20150265549-A1 STABLE AQUEOUS FORMULATION OF (E)-4-CARBOXYSTYRYL-4-CHLOROBENZYL SULFONE TTPA, EBP, ADH1A KMT2A 4634/4885MEN1 3813/4885PTGES2 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.